ストックスクリーナーアプリを入手
1.4371
6.85%
0.0921
前日終値:
$1.345
開ける：
$1.36
24時間の取引高:
15,064
Relative Volume:
0.97
時価総額：
$51.38M
収益：
-
当期純損益:
$-41.36M
株価収益率:
-0.8763
EPS:
-1.64
ネットキャッシュフロー:
$-42.09M
1週間 パフォーマンス:
+1.20%
1か月 パフォーマンス:
+10.55%
6か月 パフォーマンス:
-39.11%
1年 パフォーマンス:
-42.29%
1日の値動き範囲:
$1.36
$1.48
1週間の範囲:
$1.29
$1.69
52週間の値動き範囲:
$0.8981
$3.45
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
名前
Armata Pharmaceuticals Inc
セクター
電話
310-655-2928
住所
4503 Glencoe Avenue, Marina del Rey, CA
ARMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.4371 | 51.38M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-06-19 | 開始されました | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc (ARMP) 最新ニュース
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
10 Best Healthcare Stocks to Invest In (May 2025) - Securities.io
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat
Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com
Suparna Mishra Sarkar - Los Angeles Times
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):